)
Ajanta Pharma (AJANTPHARM) investor relations material
Ajanta Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 revenue from operations rose 33% YoY to ₹1,794 crore; PAT increased 49% to ₹388 crore, and adjusted EBITDA excluding forex loss rose 47% to ₹543 crore.
H1 revenue from operations grew 29% to ₹3,420 crore; PAT rose 40% to ₹722 crore and adjusted EBITDA excluding forex loss increased 34% to ₹997 crore.
Branded generics accounted for 66% of sales in Q2 and H1; US generics also delivered strong growth in both periods.
Financial highlights
Q2 gross profit rose 36% to ₹1,409 crore; gross margin was 79%, versus 77% in Q2 FY26.
Q2 reported EBITDA was ₹543 crore, up 66% YoY; adjusted EBITDA excluding forex MTM was ₹543 crore, up 47%, at a 30% margin.
H1 reported EBITDA was ₹971 crore, up 43%, at a 28% margin; adjusted EBITDA excluding ₹26 crore of forex loss was ₹997 crore, up 34%, at a 29% margin.
H1 gross profit grew 31% to ₹2,707 crore at a 79% margin; PAT margin was 21% in H1 and 22% in Q2.
Outlook and guidance
FY27 consolidated revenue growth guidance remains high teens; regional guidance is high single digits for US generics, mid-teens for Asia and India, and high double digits for Africa branded generics.
FY27 gross margin is guided at ~78% ±100 bps and EBITDA margin at ~27% ±100 bps; lower H2 margins are expected as US and institutional sales normalize and investment rises.
FY27 R&D guidance is ~5% of revenue, tax rate ~26.5%, and capex ~₹400 crore.
H2 growth is expected to remain robust but may be slightly below H1 momentum.
- African institutional contraction cut revenue, while India and US growth cushioned the decline.AJANTPHARM
Q4 18/19 - US generics and diversified branded growth lifted FY20 revenue 26%.AJANTPHARM
Q4 19/20 - Revenue rose 12% and PAT 40% as diversified pharma markets powered through COVID-19.AJANTPHARM
Q4 20/21 - Branded Generics drove 16% revenue growth as normalized spending and segment headwinds pressured margins.AJANTPHARM
Q4 21/22 - Revenue grew 6%, but new-plant costs and R&D pressure cut FY18 profit 8%.AJANTPHARM
Q4 17/18 - FY17 profit rose 22% as U.S. launches and India growth offset emerging-market weakness.AJANTPHARM
Q4 16/17 - Formulation-led exports and R&D gains offset bulk-plant exit costs.AJANTPHARM
Q4 99/00 - FY14 revenue rose 30%, PAT more than doubled and EBITDA margin reached 31%.AJANTPHARM
Q4 13/14 - FY15 revenue rose 23%, PAT 32%, and EBITDA margin reached 34%.AJANTPHARM
Q4 14/15
)
)
)
)
)
)
)
)